8-K: Verastem Oncology Reports Positive Pancreatic Cancer Trial Results

Verastem Oncology announced positive updated safety and efficacy results from the RAMP 205 trial evaluating avutometinib plus defactinib in combination with chemotherapy for first-line metastatic pancreatic cancer.

Summary

• Verastem Oncology announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a trial evaluating avutometinib plus defactinib in combination with standard-of-care chemotherapy in first-line metastatic pancreatic ductal carcinoma (mPDAC).
• The trial cohort included 29 patients, with 90% presenting with metastatic disease at diagnosis.
• As of the June 5, 2026 data cutoff, with a median follow-up of 9.8 months, the combination therapy demonstrated an 86% overall survival rate at 6 months.
• Progression-free survival (PFS) at six months was 68%, and the confirmed objective response rate (ORR) was 52%.
• A majority of patients (83%) experienced tumor shrinkage, and nine patients remain on treatment.
• No new safety signals were observed, with adverse events consistent with the previously reported profile.
• The company also announced the first patient dosed in the TARGET-D 201 Phase 2 trial for VS-7375, an investigational KRAS G12D inhibitor, for second-line mPDAC.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive announcement due to the strong efficacy signals in a challenging cancer indication and the advancement of a new investigational drug.

Positives

• Demonstrated an 86% overall survival rate at 6 months in the RAMP 205 trial.
• Achieved a 68% progression-free survival rate at 6 months.
• Confirmed objective response rate (ORR) of 52% in the RAMP 205 trial.
• 83% of patients experienced tumor shrinkage.
• Nine patients remain on treatment in the RP2D cohort.
• No new safety signals were observed in the RAMP 205 trial.
• First patient dosed in the TARGET-D 201 Phase 2 trial for VS-7375.

Negatives

• The five-year survival rate for pancreatic cancer remains approximately 3%, indicating a high unmet need.
• Continued approval for the AVMAPKI FAKZYNJA CO-PACK indication for LGSOC may be contingent upon verification of clinical benefit in a confirmatory trial.
• The combination therapy is investigational and not approved by the FDA for these uses.

Risks

• Potential for negative or unexpected results in ongoing clinical trials.
• The development and commercialization of product candidates may take longer or cost more than planned.
• Data may not be available when expected.
• Risks associated with preliminary and interim data, which may not be representative of more mature data.
• Regulatory uncertainty due to changes in administration policy or actions.
• Potential disruptions and delays in FDA review and oversight due to workforce reductions.
• Product candidates may not receive regulatory approval or become commercially successful.
• The company's business is subject to substantial risks and uncertainties detailed in its SEC filings.

Future Outlook

The company will continue to evaluate the potential role of avutometinib plus defactinib in metastatic pancreatic cancer, including future development opportunities and potential strategic collaborations, informed by final overall survival results from the RAMP 205 study and emerging data from VS-7375. Data from RAMP 205 will be assessed for potential presentation at a future medical meeting.

Management Comments

• "The RAMP 205 trial was designed to evaluate whether simultaneous inhibition of KRAS-driven signaling and FAK-mediated resistance pathways, in combination with standard-of-care chemotherapy, could improve outcomes for patients living with metastatic pancreatic cancer."
• "While pancreatic cancer remains one of the most challenging cancers to treat, the early survival trends and deep responses observed in this study indicate that avutometinib and defactinib are combinable with standard-of-care chemotherapy and may help overcome resistance mechanisms inherent in pancreatic cancer and support further exploration of strategies designed to address oncogenic signaling and mechanisms of treatment resistance."
• "We will continue to evaluate the potential role of avutometinib plus defactinib in metastatic pancreatic cancer, including future development opportunities and potential strategic collaborations, informed by the final overall survival results from the study as well as emerging data from VS-7375, our investigational potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, currently being evaluated in metastatic pancreatic cancer as both a monotherapy and in combination regimens."
• "We will also assess opportunities to share these data in the future, including at a medical meeting."

Industry Context

StockSavvy.ai notes that the positive results in first-line metastatic pancreatic cancer, a notoriously difficult-to-treat disease with a high unmet need, are significant. The combination therapy targets key pathways (RAS/MAPK and FAK) implicated in pancreatic cancer growth and resistance, aligning with industry trends towards targeted combination therapies. The advancement of VS-7375, a KRAS G12D inhibitor, also reflects the industry's focus on developing therapies for specific genetic mutations within pancreatic cancer.

Comparison to Industry Standards

• The 6-month overall survival rate of 86% in the RAMP 205 trial appears strong compared to historical benchmarks for first-line metastatic pancreatic cancer, where the five-year survival rate is approximately 3% and median overall survival is often less than one year with standard chemotherapy alone.
• The objective response rate (ORR) of 52% is competitive, considering that ORRs for standard chemotherapy regimens in first-line mPDAC typically range from 20-30%.
• The progression-free survival (PFS) rate of 68% at 6 months also suggests a potential benefit over standard-of-care, which generally yields shorter PFS.
• The company's investigational combination therapy is being compared against standard-of-care chemotherapy (gemcitabine and nab-paclitaxel), which is the current industry standard for first-line treatment of mPDAC.

Stakeholder Impact

• Shareholders: Potential positive impact on stock price due to promising clinical trial results and advancement of pipeline drugs.
• Patients: Potential for improved treatment options and outcomes for patients with metastatic pancreatic cancer.
• Healthcare Providers: Provides new data and potential therapeutic options for treating mPDAC.
• Researchers: Contributes to the understanding of RAS/MAPK pathway-driven cancers and potential resistance mechanisms.

Next Steps

• Continue to evaluate the potential role of avutometinib plus defactinib in metastatic pancreatic cancer.
• Consider future development opportunities and potential strategic collaborations.
• Await final overall survival results from the RAMP 205 study.
• Evaluate emerging data from VS-7375.
• Assess opportunities to share RAMP 205 data at a medical meeting.
• Conduct confirmatory trials for AVMAPKI FAKZYNJA CO-PACK if required.

Key Dates

Recommendation

The positive updated results from the RAMP 205 trial, demonstrating significant improvements in overall survival, progression-free survival, and objective response rates in a difficult-to-treat indication like first-line metastatic pancreatic cancer, coupled with the dosing of the first patient in the VS-7375 trial, present a compelling case for a strong buy. These developments suggest a strong potential for pipeline advancement and future commercial success, warranting a higher conviction rating.

Keywords

pancreatic cancer, metastatic pancreatic cancer, RAMP 205, avumentinib, defactinib, chemotherapy, KRAS G12D, VS-7375